AI-driven multi-omics drug repurposing nominates AZD7762 as a multitarget inhibitor of IL22RA1 and FAM221A in esophageal squamous cell carcinoma - PubMed
5 hours ago
- #esophageal cancer
- #multi-omics
- #drug repurposing
- The study developed an AI-driven multi-omics pipeline for esophageal squamous cell carcinoma (ESCC) to link prognostic modeling with drug repurposing.
- It identified IL22RA1 and FAM221A as key druggable genes associated with ESCC progression, using methods like Mendelian randomization and single-cell RNA sequencing.
- Machine learning and molecular docking nominated the checkpoint kinase inhibitor AZD7762 as a multitarget inhibitor of IL22RA1 and FAM221A.
- In vitro experiments confirmed that IL22RA1 and FAM221A promote ESCC cell proliferation, migration, and invasion.
- The framework provides a prognostic model, defines ESCC subgroups, and proposes AZD7762 as a repurposed drug candidate for precision oncology.